1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211209 | --- | --- | --- | --- | --- | |---------------|----------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------| | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 其他（线上电话会议） | | | | | 参与单位 | | | 中银证券、交银施罗德基金、建信基金、富国基金、华夏久盈、华 | | | 名称及人 | 宝信托 | | | | | 员姓名 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211101 | --- | --- | --- | --- | --- | |-------------------|-------------------------------------|------------------------------------------------------------|----------------------------|-------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中银证券邓周宇、杨志威、梁端玉，交银施罗德基金、重阳投资胡 | | | | 名称及人 | | 敏、兴业基金代鹏举、尚石投资贾鹏飞、德睿恒丰江昕、合正普惠 | | | | 员姓名 | | 投资原芳、南银理财钱晟、汇华理财张昕 | | | | 时间 20 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211129 | --- | --- | --- | --- | --- | --- | --- | |----------|------------------------------------------------|----------------------------------------|-------------------------|-------|---------------------------------------------------------------|-------| | | | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | | | 别 | 新闻发布会 | 路演活动 | | | | | | | 现场参观 | | | | | | | | 其他（线上电话会议） | | | | | | | 参与单位 | | 线下调研：中信证券、银河证券、淳阳基金 | | | | | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20220107 | --- | --- | --- | --- | |------------|--------------------------------------------------------------|---------------------------------------------------------|-------| | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | 系活动类 | 媒体采访 | 业绩说明会 | | | 别 | 新闻发布会 | 路演活动 | | | | 现场参观 | | | | | 其他（线上电话会议） | | | | 参与单位 | 工银瑞信基金 | | | | 名称及人 | | | | | 员姓名 | | | | | 时间 2022 | 年 1 月 7 日 | 9:30-12:00 | | | | 地点 公司会议室、重庆北部宽仁医院 | | | | 上市公司 | 董事、董事会秘书：彭云辉 | | | | 接待人员 | 投资者关系 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥3,481,328,298.92, representing a 20.80% increase year-over-year[4] - Net profit attributable to shareholders decreased by 6.21% to ¥157,107,051.58 for the quarter, while year-to-date net profit increased by 37.73% to ¥717,022,611.56[4] - The net profit for the current period reached ¥1,342,581,873.08, a significant increase from ¥715,999,282.39 in the previous period, representing an increase of approximately 87.2%[28] - Operating profit for the current period was ¥1,818,006,436.61, compared to ¥923,649,475.63 in the previous period, indicating an increase of about 96.8%[28] - Total operating revenue for the current period reached ¥10,180,991,733.93, an increase of 17.98% compared to ¥8,629,345,347.58 in the previous period[25] - The company reported a total comprehensive income of ¥1,553,326,463.12, compared to ¥721,527,099.20 in the previous period, which is an increase of approximately 115.5%[28] - Earnings per share (EPS) for the current period was ¥0.3621, up from ¥0.2629 in the previous period, representing an increase of about 37.8%[28] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥1,888,672,141.44, showing a significant increase of 136.41% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥1,888,672,141.44, compared to ¥798,903,991.74 in the previous period, marking an increase of about 136.4%[31] - The cash inflow from investment activities totaled ¥6,399,652,310.89, compared to ¥5,983,905,914.21 in the previous period, indicating an increase of approximately 6.9%[31] - The company’s cash outflow from investment activities was ¥6,423,466,215.24, slightly higher than ¥6,166,690,319.17 in the previous period, reflecting an increase of about 4.2%[31] - The net increase in cash and cash equivalents was $1,017,905,834.60, significantly higher than $427,130,522.60 previously[34] - The ending balance of cash and cash equivalents reached $3,520,862,118.20, up from $2,643,608,645.75[34] Assets and Liabilities - The total assets of the company as of the end of the reporting period were ¥30,852,486,707.32, reflecting a 2.69% increase from the end of the previous year[7] - Total assets increased to ¥30,852,486,707.32, compared to ¥30,044,426,750.47 in the previous period, marking a growth of 2.68%[24] - Total liabilities decreased slightly to ¥14,059,741,767.02 from ¥14,220,677,628.50, a reduction of 1.13%[24] - The equity attributable to shareholders of the parent company rose to ¥10,476,928,031.26, up from ¥10,109,391,327.10, indicating a growth of 3.63%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 87,819, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71% of shares[13] - The total number of shares held by the top ten shareholders includes 370,449,804 shares held by Tibet Huibang Technology Co., Ltd., which is the only shareholder with over 10% ownership[13] - The company has a total of 30 million shares held by Jiang Xueping, with no shares pledged[17] Operational Metrics - Total operating costs amounted to ¥8,815,184,892.05, up 10.31% from ¥7,993,861,821.86 in the prior period[25] - Research and development expenses increased to ¥286,550,552.75, reflecting a rise of 29.15% from ¥221,884,196.23 year-over-year[25] - The company experienced a significant increase in accounts receivable, which rose by 95.05% to ¥186,284,511.53, mainly due to an increase in bank acceptance bills received during the reporting period[9] - The company reported trading financial assets of approximately ¥753.37 million, down from ¥1.03 billion, representing a decrease of about 27%[18] Strategic Outlook - The company has not disclosed any new product developments or market expansion strategies in the current report[20] - There are no significant mergers or acquisitions reported in the current quarter[20] - The company is focusing on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[27] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[28]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 6,699,663,435.01, representing a 16.57% increase compared to CNY 5,747,430,593.16 in the same period last year[29]. - Net profit attributable to shareholders was CNY 559,915,559.98, a 58.58% increase from CNY 353,089,837.24 year-on-year[29]. - The net profit after deducting non-recurring gains and losses was CNY 557,705,491.22, up 65.40% from CNY 337,195,539.53 in the previous year[29]. - Basic earnings per share increased to CNY 0.2828, reflecting a growth of 58.61% compared to CNY 0.1783 in the same period last year[29]. - The company reported a net cash flow from operating activities of CNY 541,238,737.12, which is a decrease of 3.72% compared to CNY 562,123,622.46 in the same period last year[29]. - The weighted average return on net assets was 5.38%, an increase of 1.72% from 3.66% in the previous year[29]. - The cost of goods sold was ¥4,052,860,818.88, which is an 18.34% increase from ¥3,424,834,627.45 in the same period last year[88]. - The company reported a significant increase in research and development expenses, totaling ¥185,278,131.46, up 12.39% from ¥164,852,509.26 year-on-year[88]. - The company’s investment income amounted to ¥421,617,643.54, accounting for 32.61% of total profit, indicating a stable income source from joint ventures[94]. - The company’s foreign sales increased by 54.00% to ¥2,856,344,679.36, while domestic sales slightly decreased by 1.27% to ¥3,843,318,755.65[89]. Strategic Developments - The company plans not to distribute cash dividends or issue bonus shares[7]. - Future plans and strategic developments are subject to market risks and do not constitute a commitment to investors[6]. - The company is actively expanding its pharmaceutical retail market while maintaining its leading position in the prescription market[39]. - The company is focused on enhancing its integrated production of raw materials and formulations, ensuring a stable supply of core products[43]. - The company is actively promoting its products through multiple channels, including pharmacies and e-commerce platforms[47]. - The company will continue to focus on academic marketing and professional promotion to expand market coverage and build an efficient marketing model in response to the significant policy changes regarding essential medicines[118]. - The company is actively exploring the outpatient retail market to increase its market share outside of hospital prescription drugs, addressing the risks of price reductions due to centralized procurement of generic drugs[118]. Product Development and Innovation - The company launched multiple functional skincare products in the first half of 2022, further enriching its product matrix in the skin health management sector[39]. - The company has expanded its product offerings in dermatology, tuberculosis, and oncology, launching multiple new products in the first half of the year, including various skincare and acne treatment products[47]. - The company has developed two Class 1 new drugs and over 20 generic drugs, with 180 patents granted, showcasing its strong innovation capabilities in the pharmaceutical sector[72]. - The company has a strong R&D team with 176 technical personnel, including 4 PhDs and 6 Master's degrees, focusing on high-end chemical products and high-performance polymer materials[67]. - The company holds 137 valid patents, including 86 invention patents, and has established partnerships with universities and research institutions to enhance innovation[67]. Market Presence and Expansion - The company has covered over 200,000 terminal points in the market by expanding into county-level, grassroots, and clinic channels, enhancing its presence in the outpatient market[50]. - The company has established partnerships with over 10 online platforms, including Alibaba Health and Meituan, to enhance its e-commerce presence[50]. - The company has formed stable strategic partnerships with international agricultural chemical companies, ensuring smooth sales channels and enhancing market presence[81]. - The company has built a solid customer base with recognized product quality and stable supply capabilities, serving markets in China, Japan, South Korea, and the United States[83]. Environmental and Safety Management - The company is committed to safety management and compliance with national safety production laws to prevent accidents in its production processes[124]. - The company has established a comprehensive safety production responsibility system and management framework, ensuring effective implementation of safety protocols[200]. - The company has implemented strict pollution discharge standards, ensuring compliance with environmental regulations[140]. - The company has established an environmental monitoring plan, with all monitoring results meeting national standards, and has publicly disclosed this information[190]. - The company has engaged third-party monitoring agencies to ensure compliance with environmental regulations, with all results published on relevant platforms[188]. - The company has implemented measures to manage foreign exchange risks, including regular price adjustments with clients and collaboration with financial institutions[123]. Social Responsibility - The company actively participated in social responsibility initiatives, with a total of 640,000 RMB spent on poverty alleviation and rural revitalization efforts[192]. - The company donated 1 million RMB to support local government pandemic prevention efforts and provided over 50,000 RMB worth of protective equipment and food[192]. Challenges and Risks - The company has faced significant impacts from uncontrollable events, such as major pandemics and natural disasters, and is implementing preventive measures to minimize these effects[129]. - The company will closely monitor the implementation of healthcare reform and regulatory policies, ensuring timely adjustments to its strategies in response to potential changes[119]. - The company has established a risk-oriented internal management system to enhance environmental protection research and development investments, addressing uncertainties in environmental policies[123].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 3,399,143,349.29, representing a 20.56% increase compared to CNY 2,819,567,735.13 in the same period last year[5] - Net profit attributable to shareholders for Q1 2022 was CNY 168,625,663.08, up 38.67% from CNY 121,602,831.86 in the previous year[5] - Basic earnings per share for Q1 2022 were CNY 0.0852, reflecting a 38.76% increase from CNY 0.0614 in the same quarter last year[5] - Operating profit for the quarter was ¥479,840,467.75, up 102.5% from ¥236,783,268.06 year-over-year[28] - Net profit attributable to the parent company was ¥168,625,663.08, representing a 38.7% increase from ¥121,602,831.86 in the previous year[32] - The company reported a total comprehensive income of ¥356,932,995.27, compared to ¥175,227,007.48 in the same quarter last year, reflecting a significant growth[32] Cash Flow - The net cash flow from operating activities reached CNY 160,139,339.82, a significant increase of 523.60% compared to a negative cash flow of CNY -37,804,090.99 in Q1 2021[5] - The company reported a net cash flow from investing activities of CNY 26,581,512.40, a 132.48% increase compared to a negative cash flow of CNY -81,838,786.30 in the same period last year[12] - The net cash flow from financing activities was CNY -143,352,411.67, a decrease of 385.88% compared to CNY 50,143,727.51 in Q1 2021, primarily due to increased dividend payments[12] - Cash flow from operating activities amounted to ¥3,158,826,074.20, an increase from ¥2,233,972,460.60 in the previous year[33] - Cash received from operating activities totaled ¥3,392,521,792.08, up from ¥2,397,775,111.68, indicating strong operational performance[36] - Cash paid for goods and services was ¥1,985,219,557.72, an increase from ¥1,239,331,951.48, reflecting higher operational costs[36] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to CNY 30,249,226,747.65, a slight increase of 0.68% from CNY 30,044,426,750.47 at the end of the previous year[5] - The total liabilities decreased by 42.88% in contract liabilities, amounting to CNY 218,861,740.26, down from CNY 383,173,729.03 at the end of the previous year[9] - The total current assets are approximately RMB 12.37 billion, slightly up from RMB 12.31 billion at the beginning of the year[20] - The total assets of the company stand at approximately RMB 30.25 billion, compared to RMB 30.04 billion at the beginning of the year[20] - The total liabilities decreased slightly to ¥14,100,637,646.86 from ¥14,220,677,628.50 year-over-year[24] - Total equity increased to ¥16,148,589,100.79 from ¥15,823,749,121.97, indicating a growth in shareholder value[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 101,127[13] - The largest shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of shares, totaling 370,449,804 shares[13] - The company has a total of 184,050,000 shares pledged by the largest shareholder[13] Investment and Expenses - The company's investment income for Q1 2022 was CNY 95,932,564.71, a substantial increase of 387.03% compared to CNY 19,697,316.47 in Q1 2021[9] - Research and development expenses were reported at ¥94,978,374.93, down from ¥101,806,073.76 in the previous year, suggesting a focus on cost management[28] - Cash received from investment income was ¥30,399,478.03, up from ¥19,265,551.30, showing improved returns on investments[36] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]

Financial Performance - The company's operating revenue for 2021 was ¥12,359,182,988.15, representing a 13.63% increase compared to ¥10,876,361,873.13 in 2020[48]. - The net profit attributable to shareholders for 2021 was ¥670,048,432.27, a 2.81% increase from ¥651,730,928.90 in 2020[48]. - The net profit after deducting non-recurring gains and losses was ¥610,107,005.64, up 7.23% from ¥568,969,100.22 in 2020[48]. - The company reported a basic earnings per share of ¥0.34 for 2021, a 3.03% increase from ¥0.33 in 2020[48]. - The weighted average return on equity for 2021 was 6.91%, slightly up from 6.87% in 2020[48]. - The company achieved total revenue of CNY 1,235.92 million, an increase of CNY 148.28 million or 13.63% year-on-year[72]. - The company's net profit attributable to shareholders in 2021 was CNY 67.00 million, reflecting a year-on-year increase of CNY 1.83 million or 2.81%[72]. - The pharmaceutical sector contributed CNY 3,003,439,934.04, accounting for 24.30% of total revenue, with a growth of 7.99% compared to the previous year[151]. - The agrochemical new materials sector generated CNY 8,118,733,393.76, representing 65.69% of total revenue, with a significant year-on-year increase of 20.47%[151]. - The tourism services sector (including tea) reported revenue of CNY 513,758,306.04, which is a decline of 12.22% from the previous year[151]. Research and Development - The company has a robust R&D team of nearly 300 people and holds over 180 authorized patents, making it a leading player in the domestic skin drug market[5]. - The company has initiated over 300 product projects in its R&D center, with more than 100 projects implemented in factories, generating significant economic benefits[84]. - The company has developed 2 new Class I drugs and over 20 generic drugs, with 18 formulations passing or deemed equivalent for consistency evaluation[134]. - The number of R&D personnel increased to 1,185 in 2021, a growth of 3.40% compared to 1,146 in 2020[177]. - R&D investment amounted to ¥335,131,044.31 in 2021, reflecting a 2.85% increase from ¥325,836,705.27 in 2020[177]. Product Development and Approvals - The company has successfully obtained drug registration approvals for several new products, including Rivaroxaban tablets and Dexamethasone sodium phosphate injection[6]. - The company has launched functional products in the skin health sector, including medical skin repair dressings and moisturizing creams, targeting multiple distribution channels[76]. - The company has introduced new products in the field of dermatology, including a new formulation of tacrolimus ointment for moderate to severe atopic dermatitis[76]. - The company received approval for the new cardiovascular treatment drug, Rivaroxaban, on January 19, 2021[168]. - The company also received approval for the drug Aminosalicylic Acid and enteric-coated granules for drug-resistant tuberculosis on January 27, 2021[168]. Market Expansion and Strategy - The company is actively developing its CDMO business, leveraging new production capacities to enhance its market position[3]. - The company aims to strengthen its leading position in the prescription market and expand its market share in the outpatient retail sector[3]. - The company has established a comprehensive medical service system through acquisitions and partnerships, including the Beijing Huasheng Rehabilitation Hospital and the Ma'an Skin Hospital chain[15]. - The company has expanded its business scope to include pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism[46]. - The company has achieved significant growth in its outpatient market share by leveraging national healthcare reforms and digital healthcare initiatives[77]. Production Capacity and Facilities - The company is expanding its production capacity with the completion of the Changshou raw material drug production base and Hanjing International raw material drug production base, expected to be operational in 2022[12]. - The company has upgraded its production facilities, increasing capacity by 4-8 times at its Shuitu and Sichuan Mingxin production bases, which are now operational and meet international standards[77]. - The company has completed the construction of its Changshou and Hanzhong raw material production bases, which are expected to commence operations in 2022[77]. - The company has established seven major production bases across five provinces, ensuring sustainable production capabilities[141]. Financial Management and Investments - The profit distribution plan approved by the board is to distribute a cash dividend of 2.20 yuan (including tax) for every 10 shares based on a total of 1,979,919,191 shares[28]. - The total investment amount for the reporting period was CNY 1,662,686,692, representing a 3.12% increase compared to CNY 1,612,386,247 in the same period last year[190]. - The company reported a total of CNY 9,248,336,128.50 in fixed and intangible assets, with significant contributions from long-term equity investments amounting to CNY 4,911,710,825.15[189]. - The company has established a comprehensive cost management system in response to the trend of healthcare cost control, ensuring stable profits through integrated production models and self-supply of key raw materials[138]. Marketing and Sales - The company has established a comprehensive marketing network covering thousands of hospitals and pharmacies nationwide, with over a thousand personnel in its pharmaceutical marketing team[135]. - The company is actively exploring e-commerce channels and has partnered with over ten major pharmaceutical e-commerce platforms[135]. - The company has strengthened its marketing channels, expanding its presence in the outpatient market and covering over 200,000 terminal points, including partnerships with major e-commerce platforms[77]. - The company has established a competitive advantage in the tourism sector through resource integration and brand development, enhancing customer satisfaction and service quality[150]. Agricultural Chemicals and New Materials - The agricultural chemicals segment has a global presence in over 20 countries, with overseas sales accounting for 50.10% of the segment's revenue in 2020, showing an increase in 2021[83]. - The agricultural chemical subsidiary, Yingtai Bio, has over 100 high-quality products in herbicides, fungicides, and insecticides, with strong market competitiveness and leading domestic market share in certain categories[141]. - The new materials business has accumulated 139 patents, including 86 invention patents, and has been recognized as a technology innovation demonstration enterprise[145]. - The company has developed core technologies for efficient and low-toxicity herbicides, focusing on safety, environmental protection, and product quality[122]. Tourism Business - The tourism business includes cableway transportation, scenic area transportation, hotel operations, and tourism performances, primarily relying on famous 5A scenic spots in Yunnan, Shaanxi, Chongqing, and Guangxi[118]. - The company operates three cableways in Yunnan's Jade Dragon Snow Mountain and three in Shaanxi's Taibai Mountain National Forest Park, being the sole operator in these scenic areas[118]. - The tourism services sector (including tea) reported revenue of CNY 513,758,306.04, which is a decline of 12.22% from the previous year[151]. Risk Management - The company has a risk control system in place for its derivative investments, including measures to manage market, liquidity, credit, operational, and legal risks[194]. - The company has established internal control procedures for its forward foreign exchange business to mitigate risks associated with currency fluctuations[194].

Financial Performance - The company's revenue for Q3 2021 was ¥2,881,914,754.42, representing a 6.37% increase year-over-year[4] - Net profit attributable to shareholders decreased by 14.73% to ¥167,515,841.88 for the same period[4] - The net profit excluding non-recurring gains and losses fell by 24.71% to ¥133,696,578.33[4] - Total operating revenue for the current period reached ¥8,629,345,347.58, an increase of 9.4% compared to ¥7,887,624,026.14 in the previous period[25] - Net profit attributable to the parent company was ¥520,605,679.12, compared to ¥513,917,103.82 in the same period last year, indicating a slight increase of about 1.3%[31] - Operating profit for the period was ¥923,649,475.63, showing a marginal increase from ¥922,759,638.29 in the previous year[30] - The company reported a total comprehensive income of ¥721,527,099.20, up from ¥585,649,826.03, marking an increase of approximately 23.1%[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥29,947,839,816.05, an increase of 6.10% compared to the end of the previous year[4] - The company's total liabilities as of September 30, 2021, were not explicitly stated but are implied to have changed in relation to the asset growth[18] - Total liabilities increased to ¥15,126,327,553.39 from ¥14,089,427,152.31, reflecting a growth of 7.4%[23] - The company's equity attributable to shareholders rose to ¥9,851,142,829.68, up from ¥9,629,493,730.58, a growth of 2.3%[23] - Current liabilities totaled ¥11,720,804,709.21, including short-term borrowings of ¥6,709,154,966.64 and accounts payable of ¥1,010,034,167.07[41] Cash Flow - Cash flow from operating activities for the year-to-date was ¥798,903,991.74, a decrease of 51.68% compared to the same period last year[4] - The net cash flow from operating activities was $798.9 million, a decrease of 51.7% compared to $1.65 billion in the previous period[35] - The total cash inflow from investment activities was $5.98 billion, down 7.2% from $6.45 billion year-over-year[35] - The net cash flow from financing activities was -$202.3 million, a significant decline from a positive $1.58 billion in the previous year[35] - The total cash and cash equivalents at the end of the period amounted to $2.64 billion, a decrease from $3.82 billion in the prior year[35] Investments and Expenditures - Investment income increased by 56.35% to ¥192,098,131.88, primarily due to higher returns from joint ventures[10] - The company has invested ¥2,870,725.43 in development expenditures, significantly higher than ¥1,483,602.28 in the previous period, reflecting an increase of 93.5%[21] - Long-term equity investments stood at $2.36 billion, unchanged from the previous period[38] Shareholder Information - The total number of common shareholders at the end of the reporting period is 94,257, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71% of shares, equating to 370,449,804 shares[11] - Shareholders' equity totaled ¥14,136,682,510.39, with total equity attributable to the parent company at ¥9,629,493,730.58[44] Operational Efficiency - The weighted average return on equity was 1.73%, down by 0.34% from the previous year[4] - The company reported a significant increase in prepayments, rising by 52.77% to ¥274,075,525.61[7] - The company’s strategic focus includes the completion of board and supervisory committee elections, enhancing governance and operational efficiency[15] Other Financial Metrics - Research and development expenses totaled ¥221,884,196.23, down from ¥238,363,372.64, representing a decrease of approximately 6.3%[30] - Financial expenses decreased significantly to ¥305,908,679.72 from ¥417,712,946.13, a reduction of about 26.7%[30] - Other comprehensive income after tax was ¥5,527,816.81, a significant recovery from a loss of ¥124,877,784.83 in the previous period[30] - The company reported a deferred income of ¥242,488,330.54, compared to ¥224,944,362.25 in the previous period, showing an increase of 7.8%[23] Compliance and Standards - The company has not audited its third-quarter report for 2021[45] - The company has implemented new leasing standards starting from 2021, affecting prior comparative data[45]

Financial Performance - The company's operating revenue for the reporting period was ¥5,747,430,593.16, an increase of 10.99% compared to ¥5,178,199,762.72 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥353,089,837.24, reflecting an increase of 11.22% from ¥317,456,578.46 year-on-year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥337,195,539.53, up 15.05% from ¥293,076,507.56 in the previous year[25]. - The basic earnings per share increased to ¥0.18, a rise of 12.50% compared to ¥0.16 in the same period last year[25]. - The total assets at the end of the reporting period were ¥29,236,215,051.14, representing a growth of 3.58% from ¥28,226,109,662.70 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company decreased by 1.01% to ¥9,531,883,848.73 from ¥9,629,493,730.58 at the end of the previous year[25]. - The net cash flow from operating activities was ¥562,123,622.46, down 2.90% from ¥578,887,795.61 in the same period last year[25]. - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The weighted average return on equity was 3.66%, an increase of 0.33% compared to 3.33% in the previous year[25]. Revenue Breakdown - The company achieved a total operating revenue of 574,743.06 million CNY, an increase of 56,923.08 million CNY, representing a year-on-year growth of 10.99%[36]. - The pharmaceutical sector generated ¥1,507,824,326.16, accounting for 26.23% of total revenue, with an 18.52% increase compared to the previous year[83]. - The agrochemical new materials sector contributed ¥3,590,674,968.46, making up 62.47% of total revenue, with a year-on-year growth of 4.73%[83]. - Revenue from the tourism services sector surged by 119.98% to ¥281,074,044.26, with a gross margin increase of 41.35%[86]. - Domestic sales accounted for 67.73% of total revenue at ¥3,892,700,903.17, reflecting a 15.94% increase year-on-year[83]. Research and Development - The company has established partnerships with major universities such as Tianjin University and China Agricultural University to enhance its research and development capabilities[54]. - The company has a strong R&D team with 159 personnel and holds a total of 136 patents, including 83 invention patents[58]. - Research and development investment was ¥164,852,509.26, showing a slight decrease of 0.84% from ¥166,251,938.71 in the previous year[79]. - The company has developed two class I new drugs and over 20 generic drugs, with several products included in national key new product plans[64]. Market Strategy and Expansion - The company maintains a strong growth trajectory across all business segments, focusing on the "big skin" business strategy[36]. - The company is expanding its product matrix to cover a wide range of skin conditions, including eczema, acne, and psoriasis[38]. - The company has established long-term partnerships with international pharmaceutical companies, enhancing its market presence in developed countries[38]. - The company is actively developing new products in the pharmaceutical and healthcare sectors, aiming to strengthen its full industry chain layout[36]. - The company has strengthened its marketing channels, covering over 200,000 terminals and establishing partnerships with over 10 e-commerce platforms, including Alibaba Health and Meituan[45]. Environmental Compliance and Management - The company is committed to environmental protection and safety management, implementing a comprehensive safety production responsibility system to minimize the risk of accidents in its agricultural chemical business[110]. - The company has implemented a multi-stage deep condensation process for process waste gas treatment, ensuring compliance with emission standards[148]. - The company has installed online monitoring systems for wastewater and air emissions to ensure compliance with environmental standards[153]. - The company has received ISO 14001:2015 environmental management system certification[161]. - The company is focused on meeting the standards for wastewater and air emissions as per local regulations[138]. Subsidiary Performance - The subsidiary Huabang Pharmaceutical generated a net profit of 168,097,427.22 RMB, contributing significantly to the overall performance[104]. - The subsidiary Yingtai Biological achieved a net profit of 201,459,640.75 RMB, impacting the company's financial results positively[104]. - The total assets of the subsidiary Yingtai Biological amount to 11,366,731,132.73 RMB, indicating strong financial health[104]. Risk Management - The company has implemented internal controls for derivative investments to mitigate risks associated with market fluctuations[102]. - The company has established a crisis management system to mitigate medical risks and enhance the training of medical staff to prevent medical accidents[109]. - The company has developed a risk-oriented internal management system to address potential increases in operational costs due to stricter environmental regulations in the agricultural sector[112]. Corporate Governance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[180]. - The company's semi-annual financial report has not been audited[182]. - There are no significant litigation or arbitration matters reported during the period[184]. - The company has no major litigation or arbitration matters during the reporting period[186].